Phase 1b/2, Open-label Study of the Safety, Efficacy and Pharmacokinetics of Letrozole Plus SHR6390 (Oral CDK4/6 Inhibitor) For the First-line Treatment of HR Positive, HER2 Negative Advanced Breast Cancer in Postmenopausal Women
Phase of Trial: Phase I/II
Latest Information Update: 25 May 2018
At a glance
- Drugs Letrozole (Primary) ; SHR 6390 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
- 15 May 2018 Status changed from not yet recruiting to recruiting.
- 03 Apr 2018 New trial record